There’s a new Phase 3 clinical trial for an oral medication, taken one time per day, that will reduce testosterone for advanced prostate cancer.

Myovant Sciences is testing their new drug, called Relugolix in a trial called, HERO. Relugolix lowers testosterone by inhibiting pituitary release of luteinizing hormone and follicle-stimulating hormone.

Todays testosterone reducing therapies require injections and the most commonly used such as Lupron start off by raising testosterone and causing a clinical flare of symptoms. Relugolix decreases testosterone within days of initiation and might enable quick  testosterone recovery when treatment ends. That would be super for men thinking abou intermittent therapy.